mPEG-PLGA from PolySciTech used in development of nanoparticle-based treatment of brain-cancer

Brain cancer is a fatal disease which is very difficult to treat. Notably, uptake to the brain from blood is very poor which prevents most pharmaceutical agents from being able to physically transport to the location of action. GSK461364A, a PlK1 inhibitor, has previously shown promise for inducing apoptosis of tumor cells. Recently, researchers at University of Massachusetts used mPEG-PLGA (AK027) and PLGA (AP041) from PolySciTech (www.polyscitech.com) to develop a nanoparticle delivery system for GSK461364A to brain cancer. This research holds promise to aid in treating this fatal disease. Read more: Velpurisiva, Praveena. "Engineering Nanomedicines for Combination Treatment of Glioblastoma Multiforme." PhD diss., University of Massachusetts Lowell, 2019. http://search.proquest.com/openview/49cd4046a581e02ea911132c4a6679ac/1?pq-origsite=gscholar&cbl=18750&diss=y

“Abstract (Abbreviated): This thesis delivers a novel combinatorial approach that is crucial to treat GBM. Patients often do not respond to higher doses of the same drug after prolonged exposure, since the tumors become refractory and develop new mutations due to tumor heterogeneity. Combination treatments are the key to address cancers, since the drugs target multiple molecular sites simultaneously and have a profound cytotoxic effect. Nanoparticles will enhance this action since they prevent non-specific targeting and enhance localization in the tumor due to enhanced permeability and retention effect. Nanomedicine increases the drug bioavailability and prevents the rapid drug degradation while avoiding over all drug exposure at once when administered into the body, thus reducing the toxic effects.”

Biotech, Pharma, Cancer, Research (BPCR) is a free, 1-day scientific networking conference hosted by Akina, Inc. on Aug 28, 2019. See more and register to attend at http://bpcrconference.com